当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Christie Stewart
Atherosclerosis, a chronic inflammatory disease of the arterial walls, is characterized by intricate cellular heterogeneity within the plaques. The identification of highly plastic and heterogeneous cell populations has added a layer of complexity to atherosclerosis research, challenging traditional cell markers used for plaque analysis. To overcome this, advanced techniques such as lineage tracing and single-cell omics have emerged, enabling a deeper understanding of different cell subsets and their functional roles. Moreover, technological advancements in lipidomics and metabolomics have provided insights into the molecular landscape of atherosclerosis, shedding light on metabolic adaptations and cellular plasticity in diseased arteries. These approaches hold potential for developing antigen-specific therapies by elucidating the adaptive immune response and identifying specific targets for intervention. The need for innovative therapeutic strategies is evident, as investment in cardiovascular drug development has lagged behind other areas of research. Targeting inflammatory responses driven by impaired immune cell activation is a promising avenue, either by focusing on specific immune cell subsets or their effectors. Additionally, site-specific therapies and timingoptimized strategies may enhance drug efficacy while minimizing side effects. Identifying key regulatory pathways controlling the phenotypic modulation of endothelial cells and vascular smooth muscle cells could pave the way for converting them into atheroprotective phenotypes. Furthermore, the integration of spatial omics techniques, protein profiling, and Mendelian randomization can provide valuable insights into the adaptive immune response, antigenspecific targets, and the potential effectiveness of pharmacological modifications. These multidimensional approaches offer the potential for personalized and targeted therapies against atherosclerosis. In conclusion, a comprehensive understanding of cellular heterogeneity, immune mechanisms, and metabolic adaptations in atherosclerosis is essential for the development of innovative therapeutic interventions. By unraveling the complexities of this disease, we can pave the way for precision medicine and improved management of atherosclerosis, thus alleviating the global burden of cardiovascular disease.